SRX3207|cas:2254693-15-5|西域试剂

SRX3207,98.92%

产品编号：Bellancom-136198| CAS NO：2254693-15-5| 分子式：C₂₉H₂₉N₇O₃S| 分子量：555.65

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-136198	￥4000.00	杭州北京（现货）
Bellancom-136198	￥6800.00	杭州北京（现货）
Bellancom-136198	￥13500.00	杭州北京（现货）
Bellancom-136198	￥22000.00	杭州北京（现货）
Bellancom-136198	￥34000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SRX3207

产品介绍

SRX3207 是具有口服活性的、首创的 Syk/PI3K 双抑制剂，其对 Syk 和 PI3Kα 的 IC₅₀ 值分别为 10.7 nM 和 861 nM。SRX3207 缓解抗肿瘤免疫抑制。

生物活性

SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC₅₀ values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.

体外研究

SRX3207 (10 μmol/L) is able to block p-AKT at concentration.
SRX3207 has sufficient solubility in water (43 μmol/L).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SRX3207 (10 mg/kg, orally) increases antitumor immune response.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LLC or B16 or B16-OVA or CT26 (1 × 10⁵) cells were injected subcutaneously into syngeneic mice.
Dosage:	10 mg/kg.
Administration:	Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.
Result:	Blocked phosphorylation of Syk at 348 site and Y525/526 site. Blocked immunosuppressive MΦ polarization. Blocked tumor growth and increased survival effectively.

体内研究

SRX3207 (10 mg/kg, orally) increases antitumor immune response.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LLC or B16 or B16-OVA or CT26 (1 × 10⁵) cells were injected subcutaneously into syngeneic mice.
Dosage:	10 mg/kg.
Administration:	Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.
Result:	Blocked phosphorylation of Syk at 348 site and Y525/526 site. Blocked immunosuppressive MΦ polarization. Blocked tumor growth and increased survival effectively.

性状

Solid

溶解性数据

In Vitro:

DMSO : 5 mg/mL (9.00 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7997 mL	8.9985 mL	17.9969 mL
5 mM	0.3599 mL	1.7997 mL	3.5994 mL
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式